The imipridones ONC201 and ONC206 from Oncoceutics Inc. have shown promise in various cancers including recurrent and metastatic neuroendocrine tumors (Clinicaltrials.gov NCT03034200) and aggressive pediatric brain tumors such as glioblastomas and high-grade gliomas via TRAIL induction along with ClpP activation and DRD2 inhibition (13, 19). This evidence concerns the gene DRD2 and central nervous system cancer.